R.J. Reynolds: FDA to continue evaluation of Camel Snus modified-risk claims

R.J. Reynolds said the Tobacco Products Scientific Advisory Committee, a scientific advisory committee of the U.S. Food and Drug Administration, “recognized that the available science supports that switching completely from cigarettes to Camel Snus can significantly reduce smokers’ risk of lung cancer and respiratory disease, although the committee was evenly divided on claims regarding oral cancer and heart disease.” To date, the FDA has not issued an MRTP marketing order. The FDA will take the TPSAC’s recommendation into consideration as it independently evaluates and makes a determination based on its own review. “We appreciate the committee’s thoughtful and robust discussion of the specific language that should appear in modified-risk advertising for Camel Snus and are pleased it agrees with some of our proposed messages. The committee’s insight should be of great value to the FDA, and we look forward to working with the FDA as it evaluates our applications,” said James Figlar, executive VP of research and development of R.J. Reynolds. R.J. Reynolds Tobacco is an indirect subsidiary of Reynolds American Inc., which is an indirect, wholly owned subsidiary of British American Tobacco.

https://thefly.com/landingPageNews.php?id=2790869